TransMedics Group, Inc. (TMDX Quick QuoteTMDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System (OCS) technology. The optimism, led by decent first-quarter 2026 results, is expected to contribute further. However, concerns due to gross margin pressure persist.

This Zacks Rank #3 (Hold) company has lost 42.3% in the year-to-date period compared with 17.7% decline in the industry. The S&P 500 has witnessed 10.3% growth in the said time frame.

The renowned organ transplant therapy provider has a market capitalization of $2.44 billion. TransMedics’ earnings yield of 2.63% compares favorably with the industry’s negative 3%. The company’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters, missed once, with the average surprise being 39.37%.

Image Source: Zacks Investment Research

Factors Favoring TMDX’s Growth

Robust Pipeline Supporting Growth: TransMedics continues to advance its long-term growth strategy through the development of next-generation OCS systems and expansion into new organ markets. The company is progressing its Gen 3.0 multi-organ platform for heart, lung and liver, featuring upgraded hardware, software and a redesigned perfusion system aimed at improving usability, reliability and operational efficiency while reducing supply chain complexity.

Clinical expansion efforts remain focused on the ENHANCE Heart and DENOVO Lung programs, with the newly introduced CHOPS active cooling device expected to support trial execution and potentially broaden the company’s commercial product portfolio over time. Beyond cardiothoracic transplants, management continues to position the kidney as a major long-term opportunity, with the OCS Kidney platform under active development and a U.S. IDE submission targeted for early 2027. The company is also enhancing its broader NOP ecosystem and digital infrastructure to improve scalability, workflow efficiency and coordination across transplant centers.

Strength in OCS Technology Driving Adoption: TransMedics’ OCS revolutionizes organ transplantation by replacing passive cold storage with a dynamic, physiologic approach that perfuses donor organs with warm, oxygenated, nutrient-rich blood. This innovation minimizes ischemic injury, allows real-time organ assessment and significantly increases the viability of organs, especially hearts and lungs, donated after circulatory death, that would otherwise go unused.

As the only FDA-approved, portable platform offering warm perfusion for heart, lung and liver transplants, the OCS standardizes care, reduces post-transplant complications and sets a new clinical benchmark in organ preservation. This positions TransMedics as a leader in the multi-billion-dollar transplant market with limited competition.

Decent Q1 Results: TransMedics delivered solid first-quarter 2026 results, driven by strong OCS case volume growth, expanding clinical adoption and continued momentum in logistics services. Growth was supported by strong liver performance, steady heart adoption and higher aviation fleet utilization within the integrated National OCS Program (NOP).

While profitability remained pressured by elevated investments in expansion and clinical programs, the company continues to execute well on its long-term growth strategy. Management remains focused on advancing the ENHANCE Heart and DENOVO Lung programs, expanding internationally and developing the OCS Kidney platform, which represents a significant long-term growth opportunity.

A Factor That Can Offset the Gains for TMDX

Gross Margin Under Pressure: TransMedics’ gross margin remained under pressure in the first quarter of 2026 as the company continued scaling its integrated NOP infrastructure and investing aggressively in future growth initiatives. Gross margin came in at approximately 58%, down 331 basis points year over year, primarily due to higher internal supply chain activity tied to NOP inventory replenishment, investments supporting the ENHANCE and DENOVO clinical programs and continued expansion of the NOP network.

The growing contribution from lower-margin logistics and service revenues also weighed on blended margin performance. Management noted that certain one-time items further pressured margins during the quarter. The company expects near-term gross margins to remain range-bound around current levels as it continues investing in international expansion, technology upgrades and logistics infrastructure before scale efficiencies and operating leverage more meaningfully materialize.

Estimate Trend

TransMedics is witnessing a negative earnings estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings moved 61 cents south to $1.85 per share.

The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $184.6 million, indicating a 17.3% improvement from the year-ago quarter’s reported number.

Key Picks

Some better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB Quick QuotePACB - Free Report) , Globus Medical (GMED Quick QuoteGMED - Free Report) and Biodesix (BDSX Quick QuoteBDSX - Free Report) .

Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.

Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted earnings per share of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.

Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.

BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.